News coverage about Aptose Biosciences (NASDAQ:APTO) (TSE:APS) has been trending somewhat positive on Monday, according to Accern Sentiment Analysis. Accern rates the sentiment of news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Aptose Biosciences earned a news sentiment score of 0.05 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 44.9968462036821 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the media headlines that may have effected Accern Sentiment’s analysis:
- Placing the Bulls-Eye Focus on Aptose Biosciences Inc. (NASDAQ:APTO) - FLBC News (flbcnews.com)
- How These Biotech Stocks are Performing? — Agenus, Aptose Biosc - KAIT Jonesboro, AR - Region 8 News, weather, sports (kait8.com)
- Analyst’s Consensus to Buy Signal: Insulet Corporation (PODD) ,Aptose Biosciences Inc. (APTO) - Street Observer (press release) (streetobserver.com)
- Tale of the Ticker: Aptose Biosciences Inc (APTO) Moves on Volume - Sheridan Daily (sheridandaily.com)
- Aptose Biosciences Inc (APTO) Relative Momentum On the Rise - Evergreen Caller (evergreencaller.com)
Shares of Aptose Biosciences (APTO) traded up 3.8466% on Monday, reaching $1.6927. The company’s stock had a trading volume of 633,393 shares. Aptose Biosciences has a 52-week low of $0.78 and a 52-week high of $3.20. The firm has a 50 day moving average of $1.35 and a 200 day moving average of $1.15. The company’s market cap is $36.82 million.
A number of research firms recently weighed in on APTO. Rodman & Renshaw assumed coverage on Aptose Biosciences in a report on Thursday, June 8th. They set a “neutral” rating for the company. Canaccord Genuity reiterated a “buy” rating and issued a $7.00 price objective on shares of Aptose Biosciences in a research report on Friday, May 12th. ValuEngine upgraded Aptose Biosciences from a “strong sell” rating to a “sell” rating in a research report on Wednesday, July 12th. Finally, HC Wainwright assumed coverage on Aptose Biosciences in a research report on Thursday, June 8th. They issued a “hold” rating on the stock. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company. Aptose Biosciences presently has a consensus rating of “Hold” and an average price target of $7.00.
COPYRIGHT VIOLATION NOTICE: “Aptose Biosciences (APTO) Receives Media Impact Rating of 0.05” was originally published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this story can be accessed at https://stocknewstimes.com/2017/08/07/aptose-biosciences-apto-receiving-somewhat-positive-media-coverage-study-finds-updated.html.
About Aptose Biosciences
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
Receive News & Ratings for Aptose Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
